Inhaled nucleic acid therapeutics for respiratory diseases: delivery barriers, translational challenges, and emerging solutions
Precision Clinical Medicine · 21.10.2026 · 9 (4)
DOI: 10.1093/pcmedi/pbag030 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Precision Clinical Medicine, online erschienen am 24.10.2026. Verfasst von Leijie Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Nanomedicine and Gene Therapy, School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China. Die Arbeit nennt 239 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science and Technology Research Program of Chongqing Education Commission of China, Chongqing Science and Technology Commission of China, National Foreign Experts Individual Program.
Abstract (Originalsprache)
Pulmonary delivery of nucleic acid therapeutics represents a transformative strategy for treating a broad spectrum of respiratory diseases, including lung cancer, pulmonary fibrosis, chronic obstructive pulmonary disease, and acute lung injury. Despite their promise, effective clinical translation is hampered by a cascade of physiological barriers spanning the airway mucus layer, mucociliary clearance, alveolar macrophage uptake, cellular internalization, and endosomal sequestration. In this review, we adopt a barrier-oriented framework to systematically dissect these extracellular, cellular, and intracellular obstacles, highlighting how disease-specific microenvironments further modulate delivery efficiency. We then critically examine emerging engineering strategies—including nanocarrier surface modifications, biomimetic vesicles, aerosol optimization, and stimuli-responsive formulations that are designed to overcome these barriers. Integrating mechanistic insights with disease-specific considerations, we analyze how distinct pulmonary pathologies necessitate tailored delivery solutions, emphasizing that successful translation requires coupling nanoengineering with the unique cellular and molecular landscapes of target tissues. Finally, we discuss translational challenges, including manufacturing scalability, long-term safety, and regulatory constraints, and outline emerging solutions that may enable next-generation inhaled nucleic acid therapies. By providing a synthesis of barrier-oriented design principles and disease-driven targeting strategies, this review offers a comprehensive roadmap for accelerating the clinical adoption of inhaled nucleic acid therapeutics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Nanomedicine and Gene Therapy, School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China.
- School of Public Health, Chongqing Medical University, Chongqing 401331, China.
- The WhiteOak Group, Inc., Rockville, MD 20855, USA.
Förderung
- Science and Technology Research Program of Chongqing Education Commission of China
- Chongqing Science and Technology Commission of China
- National Foreign Experts Individual Program
- Graduate Scientific Research and Innovation Foundation of Chongqing of PR China
Zitieren
APA
Yu, L., Zhou, C., Cheng, X., Zhao, X., Yi, X., Tang, Y., Su, K., Qiao, F., Xie, J., & Lee, R. J. (2026). Inhaled nucleic acid therapeutics for respiratory diseases: delivery barriers, translational challenges, and emerging solutions. Precision Clinical Medicine, 9(4). https://doi.org/10.1093/pcmedi/pbag030
Vancouver
Yu L, Zhou C, Cheng X, Zhao X, Yi X, Tang Y, et al. Inhaled nucleic acid therapeutics for respiratory diseases: delivery barriers, translational challenges, and emerging solutions. Precision Clinical Medicine. 2026;9(4). doi:10.1093/pcmedi/pbag030
BibTeX
@article{Yu2026,
author = {Yu, Leijie and Zhou, Chongrui and Cheng, Xiang and Zhao, Xia and Yi, Xingru and Tang, Yaqin and Su, Keyu and Qiao, Fangyu and Xie, Jing and Lee, Robert J},
title = {Inhaled nucleic acid therapeutics for respiratory diseases: delivery barriers, translational challenges, and emerging solutions},
journal = {Precision Clinical Medicine},
year = {2026},
volume = {9},
number = {4},
doi = {10.1093/pcmedi/pbag030}
}
EUVIMED